ArticleJournal of gynecologic oncology2018
Trends of low-grade serous ovarian carcinoma in the United States.
Article in Journal of gynecologic oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- A pilot translational study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma.Nature communications · 2026Trial
- Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Response to Sotorasib in a patient with recurrent KRAS G12C-mutated low-grade serous ovarian cancer: a case report and literature review.Gynecologic oncology reports · 2026Article
- Serous borderline ovarian tumor and low-grade serous ovarian cancer.Abdominal radiology (New York) · 2026Review
- Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based onInternational journal of molecular sciences · 2026Article
- A Rare Presentation of Advanced-Stage Low-Grade Serous Carcinoma in a 27-Year-Old Patient. Navigating a Complex Postoperative Course: Submassive Pulmonary Embolism and a Large Retroperitoneal Haematoma Following Radical Ovarian Cytoreductive Surgery.Clinical case reports · 2025Article
- Landscape of genomic alterations and clinical outcomes in low-grade serous ovarian cancer in Korea.Gynecologic oncology reports · 2025Article
- Risk Factors for Recurrence in Serous Borderline Ovarian Tumors and Early-Stage Low-Grade Serous Ovarian Carcinoma.Current oncology (Toronto, Ont.) · 2025Article
- Molecular changes driving low-grade serous ovarian cancer and implications for treatment.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2024Review
- Targeted Therapies in Low-Grade Serous Ovarian Cancers.Current treatment options in oncology · 2024Review
- Primary ovarian cancer combined with primary fallopian tube cancer: A case report.World journal of clinical cases · 2024Article
- Exploring novel approaches in the systemic therapy of low-grade serous carcinoma of the ovary: a literature review.Frontiers in medicine · 2024Review
- Low-grade serous ovarian cancer: expert consensus report on the state of the science.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2023Article
- The highs and lows of serous ovarian cancer.Cancer · 2023Review
- Stage, treatment and survival of low-grade serous ovarian carcinoma in the Netherlands: A nationwide study.Acta obstetricia et gynecologica Scandinavica · 2023Article
- Underlying mechanisms of change in cancer prevalence in older U.S. adults: contributions of incidence, survival, and ascertainment at early stages.Cancer causes & control : CCC · 2022Article
- Versican secreted by the ovary links ovulation and migration in fallopian tube derived serous cancer.Cancer letters · 2022Article
- CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer-A Multicenter Analysis.Cancers · 2022Article
- Low-Grade Serous Carcinoma of the Ovary: The Current Status.Diagnostics (Basel, Switzerland) · 2022Review
- STING pathway expression in low-grade serous carcinoma of the ovary: an unexpected therapeutic opportunity?The journal of pathology. Clinical research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.